Hepatocellular carcinoma. Diagnosis, management, and prognosis

Surgical Oncology Clinics of North America

Volumn 23, Issue 2, 2014, Pages 289-311

  Page, Andrew J ^a   Cosgrove, David C ^a   Philosophe, Benjamin ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Hepatocellular carcinoma; Locoregional therapy; Sorafenib; Transarterial chemoembolization (TACE); Transplantation

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BRIVANIB; CISPLATIN; DECARBOXYPROTHROMBIN; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; INTERFERON; OSTEOPONTIN; OXALIPLATIN; PLACEBO; SCATTER FACTOR; SOMATOMEDIN C; SORAFENIB; SUNITINIB; TALAPORFIN; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTIFICIAL EMBOLISM; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOEMBOLIZATION; CRYOABLATION; DIAGNOSTIC ACCURACY; DIARRHEA; DRUG TARGETING; FATIGUE; HAND FOOT SYNDROME; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEREDITY; HUMAN; LASER SURGERY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MICROWAVE THERAPY; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; RADIOFREQUENCY ABLATION; RECOMMENDED DRUG DOSE; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMIC THERAPY; THERAPY EFFECT; TRANSARTERIAL RADIOEMBOLIZATION; UNSPECIFIED SIDE EFFECT;

HEPATOCELLULAR CARCINOMA; LOCOREGIONAL THERAPY; SORAFENIB; TRANSARTERIAL CHEMOEMBOLIZATION (TACE); TRANSPLANTATION;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PROGNOSIS;

EID: 84896700477     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.10.006     Document Type: Review

References (161)

1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-2576.
2. Nishida N., Kudo M. Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. Oncology 2013, 84(Suppl 1):93-97.
3. Totoki Y., Tatsuno K., Yamamoto S., et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 2011, 43(5):464-469.
4. Li M., Zhao H., Zhang X., et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet 2011, 43(9):828-829.
5. Guichard C., Amaddeo G., Imbeaud S., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012, 44(6):694-698.
6. Huang J., Deng Q., Wang Q., et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012, 44(10):1117-1121.
7. Hoshida Y., Fuchs B.C., Tanabe K.K. Genomic risk of hepatitis C-related hepatocellular carcinoma. JHepatol 2012, 56(3):729-730.
8. Arzumanyan A., Reis H.M., Feitelson M.A. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013, 13(2):123-135.
9. Yamashita T., Budhu A., Forgues M., et al. Activation of hepatic stem cell marker EpCAM by Wnt-β-catenin signaling in hepatocellular carcinoma. Cancer Res 2007, 67(22):10831-10839.
10. Monk M., Holding C. Human embryonic genes re-expressed in cancer cells. Oncogene 2001, 20(56):8085-8091.
11. Zhao R.C., Zhu Y.S., Shi Y. New hope for cancer treatment: exploring the distinction between normal adult stem cells and cancer stem cells. Pharmacol Ther 2008, 119(1):74-82.
12. Vrancken K., Paeshuyse J., Liekens S. Angiogenic activity of hepatitis B and C viruses. Antivir Chem Chemother 2012, 22(4):159-170.
13. Sanz-Cameno P., Martín-Vílchez S., Lara-Pezzi E., et al. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. Am J Pathol 2006, 169(4):1215-1222.
14. Abe M., Koga H., Yoshida T., et al. Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-κB/hypoxia-inducible factor-1α axis under hypoxic conditions. Hepatol Res 2012, 42(6):591-600.
15. Keith B., Simon M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129(3):465-472.
16. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. NEngl J Med 2008, 359(4):378-390.
17. van der Molen R.G., Sprengers D., Binda R.S., et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004, 40(3):738-746.
18. Yoo Y., Ueda H., Park K., et al. Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. JClin Invest 1996, 97(2):388.
19. Lopes A.R., Kellam P., Das A., et al. Bim-mediated deletion of antigen-specific CD8+ T cells in patients unable to control HBV infection. JClin Invest 2008, 118(5):1835.
20. Guidotti L.G., Chisari F.V. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006, 1:23-61.
21. Fazle Akbar S., Inaba K., Onji M. Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon-γ: abrogation of immune response defect to a T-cell-dependent antigen. Immunology 1996, 87(4):519-527.
22. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53(3):1020-1022.
23. Sherman M. Serological surveillance for hepatocellular carcinoma: time to quit. JHepatol 2010, 52(4):614-615.
24. Sherman M. Screening for hepatocellular carcinoma. Hepatol Res 2007, 37(s2):S152-S165.
25. Yuen M.F., Lai C.L. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005, 19(1):91-99.
26. Li D., Mallory T., Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001, 313(1):15-19.
27. Staden L.V., Bukofzer S., Kew M.C., et al. Differential lectin reactivities of α-fetoprotein in hepatocellular carcinoma: diagnostic value when serum α-fetoprotein levels are slightly raised. JGastroenterol Hepatol 1992, 7(3):260-265.
28. Yamashita F., Tanaka M., Satomura S., et al. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996, 111(4):996-1001.
29. Toyoda H., Kumada T., Tada T., et al. Clinical utility of highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/mL. Cancer Sci 2011, 102(5):1025-1031.
30. Aoyagi Y., Oguro M., Yanagi M., et al. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996, 77(9):1781-1786.
31. Marrero J.A., Su G.L., Wei W., et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003, 37(5):1114-1121.
32. Ikoma J., Kaito M., Ishihara T., et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-γ-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002, 49(43):235-238.
33. Hamamura K., Shiratori Y., Shiina S., et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-γ-carboxy prothrombin and low serum α-fetoprotein. Cancer 2000, 88(7):1557-1564.
34. Koike Y., Shiratori Y., Sato S., et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer 2001, 91(3):561-569.
35. Tateishi R., Yoshida H., Matsuyama Y., et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review 2008, 2(1):17-30.
36. Anborgh P.H., Mutrie J.C., Tuck A.B., et al. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. JCell Mol Med 2010, 14(8):2037-2044.
37. Ye Q.H., Qin L.X., Forgues M., et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003, 9(4):416-423.
38. Shang S., Plymoth A., Ge S., et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012, 55(2):483-490.
39. Moon W.S., Rhyu K.H., Kang M.J., et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?. Mod Pathol 2003, 16(6):552-557.
40. Poon R., Ho J., Tong C., et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004, 91(10):1354-1360.
41. Kaseb A.O., Morris J.S., Hassan M.M., et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. JClin Oncol 2011, 29(29):3892-3899.
42. Nakatsura T., Yoshitake Y., Senju S., et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003, 306(1):16-25.
43. Nakamura T. Structure and function of hepatocyte growth factor. Prog Growth Factor Res 1991, 3(1):67-85.
44. Yamagamim H., Moriyama M., Matsumura H., et al. Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. Cancer 2002, 95(4):824-834.
45. Mazziotti G., Sorvillo F., Morisco F., et al. Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Cancer 2002, 95(12):2539-2545.
46. Asiyanbola B., Chang D., Gleisner A.L., et al. Operative mortality after hepatic resection: are literature-based rates broadly applicable?. JGastrointest Surg 2008, 12(5):842-851.
47. Parikh A.A., Gentner B., Wu T.T., et al. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. JGastrointest Surg 2003, 7(8):1082-1088.
48. Joh J.W., Johnson P.J., Monden M., et al. Biology of hepatocellular carcinoma. Ann Surg Oncol 2008, 15(4):962-971.
49. Brouquet A., Andreou A., Shindoh J., et al. Methods to improve resectability of hepatocellular carcinoma. Multidisciplinary treatment of hepatocellular carcinoma 2013, 57-67. Springer.
50. Chun Y.S., Ribero D., Abdalla E.K., et al. Comparison of two methods of future liver remnant volume measurement. JGastrointest Surg 2008, 12(1):123-128.
51. Kubota K., Makuuchi M., Kusaka K., et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology 1997, 26(5):1176-1181.
52. Manizate F., Hiotis S.P., Labow D., et al. Liver functional reserve estimation: state of the art and relevance to local treatments. Oncology 2010, 78(Suppl. 1):131-134.
53. Pugh R., Murray-Lyon I., Dawson J., et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60(8):646-649.
54. Santambrogio R., Kluger M.D., Costa M., et al. Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh's A cirrhosis: is clinical evidence of portal hypertension a contraindication?. HPB (Oxford) 2013, 15(1):78-84.
55. Cucchetti A., Ercolani G., Vivarelli M., et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl 2006, 12(6):966-971.
56. Delis S.G., Bakoyiannis A., Biliatis I., et al. Model for end-stage liver disease (MELD) score, as a prognostic factor for post-operative morbidity and mortality in cirrhotic patients, undergoing hepatectomy for hepatocellular carcinoma. HPB (Oxford) 2009, 11(4):351-357.
57. Delis S.G., Bakoyiannis A., Dervenis C., et al. Perioperative risk assessment for hepatocellular carcinoma by using the MELD score. JGastrointest Surg 2009, 13(12):2268-2275.
58. Wong T., Lo C.M. Resection strategies for hepatocellular carcinoma. Semin Liver Dis 2013, 33:273-281. Thieme.
59. Hoekstra L.T., de Graaf W., Nibourg G.A., et al. Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg 2013, 257(1):27-36.
60. Hemming A.W., Reed A.I., Howard R.J., et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003, 237(5):686.
61. Farges O., Belghiti J., Kianmanesh R., et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003, 237(2):208.
62. Abdalla E.K., Barnett C.C., Doherty D., et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002, 137(6):675.
63. Ribero D., Abdalla E., Madoff D., et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007, 94(11):1386-1394.
64. Lee K.K., Kim D.G., Moon I.S., et al. Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. JSurg Oncol 2010, 101(1):47-53.
65. Zhou X.D., Tang Z.Y., Yang B.H., et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001, 91(8):1479-1486.
66. Pawlik T.M., Poon R.T., Abdalla E.K., et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005, 137(4):403-410.
67. Yamashita Y., Taketomi A., Itoh S., et al. Longterm favorable results of limited hepatic resections for patients with hepatocellular carcinoma: 20 years of experience. JAm Coll Surg 2007, 205(1):19-26.
68. Poon R.T., Fan S.T., Lo C.M., et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002, 235(3):373.
69. Shi M., Guo R.P., Lin X.J., et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 2007, 245(1):36.
70. Nathan H., Hyder O., Mayo S.C., et al. Surgical therapy for early hepatocellular carcinoma in the modern era. Ann Surg 2013, [Epub ahead of print].
71. Pawlik T.M., Delman K.A., Vauthey J.N., et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005, 11(9):1086-1092.
72. Nagasue N., Kohno H., Chang Y.C., et al. Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993, 217(4):375.
73. Wang B.W., Mok K.T., Liu S.I., et al. Is hepatectomy beneficial in the treatment of multinodular hepatocellular carcinoma?. JFormos Med Assoc 2008, 107(8):616-626.
74. Ishizawa T., Hasegawa K., Aoki T., et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008, 134(7):1908-1916.
75. Truty M.J., Vauthey J.N. Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol 2010, 17(5):1219-1225.
76. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. NEngl J Med 1996, 334(11):693-700.
77. Lai E.C., Ng I.O., Ng M.M., et al. Long-term results of resection for large hepatocellular carcinoma: a multivariate analysis of clinicopathological features. Hepatology 1990, 11(5):815-818.
78. Wu C.C., Ho Y.Z., Ho W.L., et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995, 82(1):122-126.
79. Régimbeau J.M., Farges O., Shen B.Y., et al. Is surgery for large hepatocellular carcinoma justified?. JHepatol 1999, 31(6):1062-1068.
80. Hanazaki K., Kajikawa S., Shimozawa N., et al. Hepatic resection for large hepatocellular carcinoma. Am J Surg 2001, 181(4):347-353.
81. Fong Y., Sun R.L., Jarnagin W., et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999, 229(6):790.
82. Poon R.T., Fan S.T., Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. JAm Coll Surg 2002, 194(5):592-602.
83. Vauthey J.N., Pawlik T.M., Lauwers G.Y., et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005, 12(5):364-373.
84. Yang L.Y., Fang F., Ou D.P., et al. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg 2009, 249(1):118-123.
85. Ikai I., Yamamoto Y., Yamamoto N., et al. Results of hepatic resection for hepatocellular carcinoma invading major portal and/or hepatic veins. Surg Oncol Clin N Am 2003, 12(1):65-75.
86. Iwatsuki S., Gordon R.D., Shaw B.W., et al. Role of liver transplantation in cancer therapy. Ann Surg 1985, 202(4):401.
87. Adam R., Azoulay D., Castaing D., et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?. Ann Surg 2003, 238(4):508.
88. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30(6):1434-1440.
89. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
90. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002, 8(9):765-774.
91. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001, 33(6):1394-1403.
92. Yao F.Y., Bass N.M., Nikolai B., et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002, 8(10):873-883.
93. Leung J.Y., Zhu A.X., Gordon F.D., et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl 2004, 10(11):1343-1354.
94. Todo S., Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004, 240(3):451.
95. Decaens T., Roudot-Thoraval F., Hadni-Bresson S., et al. Impact of UCSF criteria according to pre-and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006, 12(12):1761-1769.
96. Duffy J.P., Vardanian A., Benjamin E., et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007, 246(3):502.
97. Onaca N., Davis G.L., Goldstein R.M., et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl 2007, 13(3):391-399.
98. Llovet J.M., Schwartz M., Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25:181-200. New York: Thieme-Stratton; c1981.
99. Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10(1):35-43.
100. Bellavance E.C., Lumpkins K.M., Mentha G., et al. Surgical management of early-stage hepatocellular carcinoma: resection or transplantation?. JGastrointest Surg 2008, 12(10):1699-1708.
101. Earl T.M., Chapman W.C. Hepatocellular carcinoma: resection versus transplantation. Semin Liver Dis 2013, 33:282-292. Thieme Medical Publishers.
102. Yao F.Y., Bass N.M., Nikolai B., et al. Afollow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003, 9(7):684-692.
103. Cescon M., Cucchetti A., Ravaioli M., et al. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. JHepatol 2013, 58(3):609-618.
104. de Lope C.R., Tremosini S., Forner A., et al. Management of HCC. JHepatol 2012, 56:S75-S87.
105. Kaihara S., Kiuchi T., Ueda M., et al. Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 2003, 75(3):S37-S40.
106. Gondolesi G.E., Roayaie S., Muñoz L., et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004, 239(2):142.
107. Fisher R., Kulik L., Freise C., et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007, 7(6):1601-1608.
108. Ghobrial R.M., Freise C.E., Trotter J.F., et al. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008, 135(2):468-476.
109. Sarasin F.P., Majno P.E., Llovet J.M., et al. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and cost-effectiveness perspective. Hepatology 2001, 33(5):1073-1079.
110. Majno P.E., Adam R., Bismuth H., et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997, 226(6):688.
111. Porrett P.M., Peterman H., Rosen M., et al. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl 2006, 12(4):665-673.
112. Decaens T., Roudot-Thoraval F., Bresson-Hadni S., et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005, 11(7):767-775.
113. Pelletier S.J., Fu S., Thyagarajan V., et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl 2009, 15(8):859-868.
114. Clavien P.A., Lesurtel M., Bossuyt P.M., et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012, 13(1):e11-e22.
115. Jarnagin W., Chapman W.C., Curley S., et al. Surgical treatment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010, 12(5):302-310.
116. Llovet J.M., Real M.I., Montaña X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359(9319):1734-1739.
117. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35(5):1164-1171.
118. Llovet J., Mas X., Aponte J., et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002, 50(1):123-128.
119. Teh S.H., Christein J., Donohue J., et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (MELD) score predicts perioperative mortality. JGastrointest Surg 2005, 9(9):1207-1215.
120. Nathan H., Schulick R.D., Choti M.A., et al. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 2009, 249(5):799-805.
121. Belghiti J., Cortes A., Abdalla E.K., et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003, 238(6):885.
122. Meza-Junco J., Montano-Loza A.J., Liu D.M., et al. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?. Cancer Treat Rev 2012, 38(1):54-62.
123. Simon C.J., Dupuy D.E., Mayo-Smith W.W. Microwave ablation: principles and applications. Radiographics 2005, 25(Suppl 1):S69-S83.
124. Lencioni R., Cioni D., Della Pina C., et al. Hepatocellular carcinoma: new options for image-guided ablation. JHepatobiliary Pancreat Sci 2010, 17(4):399-403.
125. Wang S., Keltner L., Winship J., et al. Aphase I/II safety and efficacy study of intratumoral light-activated drug therapy using talaporfin sodium in patients with inoperable hepatocellular carcinoma. JClin Oncol (Meeting Abstracts) 2009, 2009:e15684.
126. Bouza C., López-Cuadrado T., Alcázar R., et al. Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol 2009, 9(1):31.
127. Orlando A., Leandro G., Olivo M., et al. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009, 104(2):514-524.
128. Llovet J.M., Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. JHepatol 2008, 48:S20-S37.
129. Brunello F., Veltri A., Carucci P., et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008, 43(6):727-735.
130. Shiina S., Teratani T., Obi S., et al. Arandomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005, 129(1):122-130.
131. Lin S., Lin C., Lin C., et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005, 54(8):1151-1156.
132. Shibata T., Iimuro Y., Yamamoto Y., et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002, 223(2):331-337.
133. Yu N.C., Lu D., Raman S.S., et al. Hepatocellular carcinoma: microwave ablation with multiple straight and loop antenna clusters-pilot comparison with pathologic findings. Radiology 2006, 239(1):269.
134. Brown D.B., Gould J.E., Gervais D.A., et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. JVasc Interv Radiol 2009, 20(7):S425-S434.
135. Acomparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. NEngl J Med 1995, 332(19):1256-1261.
136. Riaz A., Memon K., Miller F.H., et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. JHepatol 2011, 54(4):695-704.
137. Lencioni R., Llovet J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010, 30:52-60. ©; Thieme Medical Publishers.
138. Bonekamp S., Jolepalem P., Lazo M., et al. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology 2011, 260(3):752-761.
139. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007, 30(1):6-25.
140. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37(2):429-442.
141. van Malenstein H., Maleux G., Vandecaveye V., et al. Arandomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 2011, 34(7):368-376.
142. Lewis A.L., Gonzalez M., Lloyd A.W., et al. DC bead: invitro characterization of a drug-delivery device for transarterial chemoembolization. JVasc Interv Radiol 2006, 17(2):335-342.
143. Lewis A.L., Gonzalez M.V., Leppard S.W., et al. Doxorubicin eluting beads- 1: effects of drug loading on bead characteristics and drug distribution. JMater Sci Mater Med 2007, 18(9):1691-1699.
144. Poon R.T., Tso W.K., Pang R.W., et al. Aphase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007, 5(9):1100-1108.
145. Lammer J., Malagari K., Vogl T., et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010, 33(1):41-52.
146. Vogl T.J., Lammer J., Lencioni R., et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. Am J Roentgenol 2011, 197(4):W562-W570.
147. Sangro B., Iñarrairaegui M., Bilbao J.I. Radioembolization for hepatocellular carcinoma. JHepatol 2012, 56(2):464-473.
148. Kim Y.H., Kim D.Y. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know. Oncology 2013, 84(Suppl 1):34-39.
149. Mazzaferro V., Sposito C., Bhoori S., et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013, 57(5):1826-1837.
150. Salem R., Mazzaferro V., Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges and clinical perspectives. Hepatology 2013, [Epub ahead of print].
151. Seinstra B.A., Defreyne L., Lambert B., et al. Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Trials 2012, 13(1):144.
152. Leung T.W., Johnson P.J. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001, 28:514-520. Elsevier.
153. Yeo W., Mok T.S., Zee B., et al. Arandomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. JNatl Cancer Inst 2005, 97(20):1532-1538.
154. Louafi S., Boige V., Ducreux M., et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC). Cancer 2007, 109(7):1384-1390.
155. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(1):25-34.
156. Furuse J., Ishii H., Nakachi K., et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008, 99(1):159-165.
157. Lencioni R., Kudo M., Ye S.L., et al. First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study. Int J Clin Pract 2012, 66(7):675-683.
158. Johnson P.J., Qin S., Park J.W., et al. Brivanib versus Sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL Study. JClin Oncol 2013, 31:3517-3524.
159. Cheng A., Kang Y., Lin D., et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). JClin Oncol 2011, 29(Suppl 15):4000.
160. Santoro A., Simonelli M., Rodriguez-Lope C., et al. Aphase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br J Cancer 2013, 108(1):21-24.
161. Buijs M., Reyes D.K., Pawlik T.M., et al. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2012, 119:1042-1049.